Sunday, May 17, 2026
  • English
  • Marathi
No Result
View All Result
Daily PRABHAT
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science
Daily PRABHAT
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
Home National

Dr YK Gupta gives clarification on speculation ‘Ranitidine’ being removed from NLEM due to cancer

by
4 years ago
in National
A A
Dr YK Gupta gives clarification on speculation ‘Ranitidine’ being removed from NLEM due to cancer
Share on FacebookShare on Twitter

New Delhi [India], September 15 (ANI): India on Tuesday dropped the antacid Ranitidine, which is sold as Zantac, from the National List of Essential Medicines 2022. It was earlier on the list of essential medicines.

According to Dr. Y K Gupta, the Professor, Vice Chairman, Standing National Committee on Medicines and Health Care Products, “Sometime back FDA noted that in some of the batches of a few drugs like Ranitidine, losartan and metphormin an impurity known as nitrosodimethylamine (NDMA) was observed. This substance can cause cancer. As a response, the FDA put some pause on such products while a detailed investigation is still awaited. It is still not established that what amount of exposure of this substance will be carcinogenic particularly when the drug is taken on as and when needed basis.”

“There are the drugs that proton pump inhibitors such as pentazole, omeprazole which are effective safe and affordable. These alternatives are already listed in NLEM and ranitidine has been deleted. The deletion of ranitidine shouldn’t cause panic in patients taking ranitidine.”

He said further, “All are advised to take medication only on the advice of the doctor as any medication if not taken appropriately may cause harm.”

“There should not be any panic or misconception that drug is banned,” Dr Gupta said.

The US FDA, in 2020 requested a manufacturer’s market withdrawal of ranitidine, known commonly by the brand name Zantac.

According to the updates on NDMA present on the FDA website, “FDA has found N-nitrosodimethylamine (NDMA) levels in some ranitidine products increase with time and temperature posing a risk to consumers, and therefore the agency has requested the withdrawal of all ranitidine products from the U.S. market. Consumers should stop taking any OTC ranitidine they may currently have.”

“People keep on taking these drugs for long duration that can give some kind of side effects. I must say that these drugs should be used for a specified duration and only under prescription and treating physician or gastroenterologist,” emphasized Dr. S Chatterjee, Internal Medicine Physician, Indraprastha Apollo Hospitals. (ANI)

ShareTweetSendShareSend

Latest News

Bhojshala issue: Around 1,000 security personnel deployed across sensitive areas in Dhar district, says ASP

Uttarakhand CM participates in district training camp under Pandit Deendayal Upadhyay Training Mahabhibhag

Rajasthan CM travels by EV bus to save fuel in line with PM Modi’s appeal for oil conservation efforts

Haryana CM launches Prashikshan Maha Abhiyan 2026

“Matter of great fortune”: Kumar Vishwas on Bhojshala case verdict

Jitendra Singh lauds of Sree Chitra Tirunal’s contribution towards indigenous medical device development

Haryana receives Geospatial Excellence Award in Netherlands, Chief Minister congratulates HARSAC team

Court denies bail to DGCA Deputy DG after noting investigation at sensitive stage in corruption case

“Nowhere is it stated that Namaz should be discontinued”: Mosque Society chief Abdul Samad says Bhojshala verdict “blatantly one-sided”

Nitish Kumar chose Samrat Choudhary as his successor to carry forward his legacy: Union Minister Lalan Singh

New Delhi [India], September 15 (ANI): India on Tuesday dropped the antacid Ranitidine, which is sold as Zantac, from the National List of Essential Medicines 2022. It was earlier on the list of essential medicines.

According to Dr. Y K Gupta, the Professor, Vice Chairman, Standing National Committee on Medicines and Health Care Products, "Sometime back FDA noted that in some of the batches of a few drugs like Ranitidine, losartan and metphormin an impurity known as nitrosodimethylamine (NDMA) was observed. This substance can cause cancer. As a response, the FDA put some pause on such products while a detailed investigation is still awaited. It is still not established that what amount of exposure of this substance will be carcinogenic particularly when the drug is taken on as and when needed basis."

"There are the drugs that proton pump inhibitors such as pentazole, omeprazole which are effective safe and affordable. These alternatives are already listed in NLEM and ranitidine has been deleted. The deletion of ranitidine shouldn't cause panic in patients taking ranitidine."

He said further, "All are advised to take medication only on the advice of the doctor as any medication if not taken appropriately may cause harm."

"There should not be any panic or misconception that drug is banned," Dr Gupta said.

The US FDA, in 2020 requested a manufacturer's market withdrawal of ranitidine, known commonly by the brand name Zantac.

According to the updates on NDMA present on the FDA website, "FDA has found N-nitrosodimethylamine (NDMA) levels in some ranitidine products increase with time and temperature posing a risk to consumers, and therefore the agency has requested the withdrawal of all ranitidine products from the U.S. market. Consumers should stop taking any OTC ranitidine they may currently have."

"People keep on taking these drugs for long duration that can give some kind of side effects. I must say that these drugs should be used for a specified duration and only under prescription and treating physician or gastroenterologist," emphasized Dr. S Chatterjee, Internal Medicine Physician, Indraprastha Apollo Hospitals. (ANI)

No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science